C10910: Use of RNA Interference and Adenovirus Therapy against Prostate Cancer
Value Proposition: • Addresses a major patient need • Enhances the therapeutic efficacy of CRAd strategy • Creates the bases to develop enhanced oncolytic viral gene therapies with shRNA
Technical Details:
Prostate cancer is one of the most aggressive cancers worldwide. Each year more than 680,000 men are diagnosed with this cancer and approximately 222,000 lose their lives. Currently, there are a limited number of treatments available. One strategy for approaching this disease has been the development of prostate-specific conditionally replicating adenoviruses (CRAds). However, the potency of these viruses has been inadequate for a single modality therapy. JHU scientists have developed a novel prostate specific CRAd using RNA interference against cyclin-dependent kinase inhibitor (p21/Waf-1) in the backbone of this virus to augment its natural life cycle. Researcher showed for the first time that knockdown of p21/Waf-1 by shRNA in prostate cancer results in increased androgen receptor expression and androgen receptor-dependent promoter activity. By inducing the promoter activity, they enhanced the therapeutic efficacy of CRAd virus.
Looking for Partners:
Replication Competent Prostate specific Gene therapy vector
Patent Status: Granted US Patent 8,859,287
Publications/Associated Cases:
Höti N. et al (2010) Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther. 17(8):585-597.
